

DAFTAR PUSTAKA

- Ahmed, S., Pahwa, P., Le D., Chalchal, H., Chandra-Kanthan, S., Iqbal, N., Fields A. 2018. Primary Tumor Location and Survival in the General Population With Metastatic Colorectal Cancer. *Clin Colorectal Cancer*. Jun;17(2):e201-e206.
- American Cancer Society. 2005. Colorectal Cancer Facts & Figures Special Edition 2005. Oklahoma City, OK: *American Cancer Society*; Available from: <http://www.cancer.org>.
- Al-Sukhni, W., Aronson, M., Gallinger, S. 2008. Hereditary colorectal cancer syndromes: familial adenomatous polyposis and lynch syndrome. *Surg Clin North Am*; 88(4):819–844.
- Boardman, L.A., Morlan, B.W., Rabe, K.G. 2007. Colorectal cancer risks in relatives of young-onset cases: is risk the same across all first-degree relatives?. *Clin Gastroenterol Hepatol*; 5(10):1195–1198.
- Cassidy, J., Saltz, L., Twelves, C., Van Cutsem, E., Hoff, P., Kang, Y., Saini, J.P., Gilberg, F., Cunningham, D. 2011. Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. *Annals of Oncology* 22: 2604–2609,
- Chandra, R.K . 1999. Nutrition and Immunology: From The Clinic to Cellular Biology and Back Again. *Proc Nutr Soc* 58: 681–3.
- Chandrasinghe, P.C., Ediriweera, D.S., Kumara, S.K., Deen, K.I. 2013. Pre-operative hypoalbuminaemia predicts poor overall survival in rectal cancer: a retrospective cohort analysis. *BMC Clin Pathol*; 13: 12
- Chibaudel, B., Bonnetain, F., Tournigand, C., Bengrine-Lefevre, L., Teixeira, L., Artru, P., Desram, J., Larsen, A.K., Andre, T., Louvet, C., Degramont, A. 2011. Simplified Prognostic Model in Patients with Oxaliplatin-Based or Irinotecan-Based First-Line Chemotherapy for Metastatic Colorectal Cancer: A GERCOR Study. *The Oncologist*;16:1228–1238
- Connolly, G.C., Khorana, A.A., Kuderer, N.M., Culakova, E., Francis, C.W., Lyman, G.H. 2010. Leukocytosis, thrombosis and early mortality in cancer patients initiating chemotherapy. *Thromb Res*. August ; 126(2): 113–118.
- Coussens, L.M., Werb, Z. 2002. Inflammation and cancer. *Nature*. 19; 420(6917): 860–867.
- Dahlan, S. 2010. Besar Sampel Penelitian. *Sagung Seto*. Jakarta.
- Davies, R.J., Miller, R., Coleman, N. 2005. Colorectal cancer screening: prospects for molecular stool analysis. *Nat Rev Cancer*; 5:199–209.
- de Gramont, A., Figuer, A., Seymour, M. 2000. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. *J Clin Oncol*; 18: 2938–2947.
- de Jong, A.E., Morreau, H., Nagengast, F.M. 2005. Prevalence of adenomas among young individuals at average risk for colorectal cancer. *Am J Gastroenterol*;100(1):139–143.
- Divitiis, C.D., Nasti, G., Montano, M., Fisichella, R., Iaffaioli, R.V., Berretta, M. 2014. Prognostic and predictive response factors in colorectal cancer

patients: Between hope and reality. *World J Gastroenterol* November 7; 20(41): 15049-15059.

- Downing, A., Aravani, A., Macleod, U., Oliver, S., Finan, P.J., Thomas J.D., Quirke, P., Wilkinson, J.R., Morris, E.J. 2013. Early mortality from colorectal cancer in England: a retrospective observational study of the factors associated with death in first year after diagnosis. *Br J Cancer*, 2013 Feb 19;108(3):681-5.
- Edge, S.B., Compton, C.C. 2010. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. *Ann Surg Oncol*, 2010 Jun;17(6):1471-4. doi: 10.1245/s10434-010-0985-4
- Falcone, A., Ricci, S., Brunetti, I. 2007. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. *J Clin Oncol*; 25: 1670–1676.
- Folprecht, G., Grothey, A., Alberts, S., Raab, H.R., Kohne, C.H. 2005. Neoadjuvant treatment of unresectable colorectal liver metastasis: correlation between tumour response and resection rates. *Annals of Oncology* 16: 1311–1319.
- Gupta, D., Lis C.G. 2010. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. *Nutr J*; 9: 69.
- Giessen, C., Stintzing, S., Laubender, R.P. 2011. Analysis for prognostic factors of 60-day mortality: evaluation of an irinotecan-based phase III trial performed in the first-line treatment of metastatic colorectal cancer. *Clin Colorectal Cancer*;10: 317–324.
- Giessen, C., Graeven, U., Laubender, R.P., Modest, D.P., Schulz, C., Porschen, R., Schmiege, W., Reinacher-Schick, A., Hegewisch-Becker, S., Stintzing, S., Heinemann V. 2013. Prognostic factors for 60-day mortality in first-line treatment of metastatic colorectal cancer (mCRC): individual patient analysis of four randomised, controlled trials by the AIO colorectal cancer study group. *Annals of Oncology* 24: 3051–3055.
- Haggar, F. A., Boushey, R.P. 2009. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. *Clin Colon Rectal Surg*, 22, 191-7.
- Heys, S.D., Walker, L.G., Deehan, D.J., Eremin, O.E. 1998. Serum albumin: a prognostic indicator in patients with colorectal cancer. *J R Coll Surg Edinb*; 43: 163-168
- Hugen, C.N., van de Velde, J.H., de Wilt, I.W., Nagtegaal, D. 2014. Metastatic pattern in colorectal cancer is strongly influenced by histological subtype. *Annals of Oncology*; 25 (3):651–657
- Hurwitz, H., Fehrenbacher, L., Novotny, W. 2004. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. *N Engl J Med*; 350: 2335–42.
- Jackson-Thompson, J., Ahmed, F., German, R.R., Lai, S.M., Friedman, C., 2006. Descriptive epidemiology of colorectal cancer in the United States, 1998–2001. *Cancer*; 107(5, Suppl): 1103–1111.

- Janout, V., Kolla'rova' H., 2001. Epidemiology of colorectal cancer. *Biomed Pap Med Fac Univ Palacku Olomouc Czech Repub*; 145:5–10.
- Jemal A., Bray, F., Center, M.M., Ferlay, J., Ward, E., Forman, D. 2011. Global cancer statistics. *CA Cancer J Clin*; 61: 69-90.
- Karapetis, C.S., Khambata-Ford, S., Jonker, D.J. 2008. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. *N Engl J Med*; 359: 1757–65.
- Köhne, C.H., Cunningham, D., Di, C.F. 2002. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. *Ann Oncol*; 13: 308–317.
- Kozloff, M.F., Berlin, J., Flynn, P.J., Kabbinavar, F., Ashby, M., Dong, W., Sing, A.P., Grothey, A. 2010. Clinical outcomes in elderly patients with metastatic colorectal cancer receiving bevacizumab and chemotherapy: results from the BRiTE observational cohort study. *Oncology*;78(5-6):329-39
- Labianca, R., Beretta, G.D., Mosconi, S., Milesi, L., Pessi, M.A. 2005. Colorectal cancer: screening. *Ann Oncol*; 16(Suppl 2): ii127–ii132.
- Lee, J., Meyerhardt, J.A., Giovannucci, E., Jeon, J.Y. 2015. Association between Body Mass Index and Prognosis of Colorectal Cancer: A Meta-Analysis of Prospective Cohort Studies. *PLoS ONE* 10(3): e0120706.
- López-Gómez, M., Casado, E., Cejas, P., Feliu, J. 2011. Prognostic and predictive factors in colorectal cancer: The importance of reliable markers for effective selection of therapy. *The Challenge of Colorectal Cancer: A Review Book*: 285-308.
- Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W. 2015. Primary tumor location as a prognostic factor in metastatic colorectal cancer. *J Natl Cancer Inst.*; 107.
- Moghadamyeghaneh, Z., Hanna, M.H., Carmichael, J.C., Mills, S.D., Pigazzi, A., Stamos, M.J. 2015. Preoperative Leukocytosis in Colorectal Cancer Patients. *Journal of the American College of Surgeons*.
- National Institutes of Health, 2006. What You Need To Know About Cancer of the Colon and Rectum. Bethesda, MD:U.S. *Department of Health and Human Services & National Institutes of Health*.
- Nozoe, T., Matono, R., Ijichi, H., Ohga, T., Ezaki, T. 2014. Glasgow Prognostic Score (GPS) Can Be a Useful Indicator to Determine Prognosis of Patients With Colorectal Carcinoma. *Int Surg*;99.
- Passardi, A., Scarpi, E., Tamperi, S., Cavanna, L., Tassinari, .D, Fontana, A., et al. 2015 Impact of Pre Treatment Lactate Dehydrogenase Levels on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer. *PLoS ONE* 10(8): e0134732.
- Ries, L.A.G., Melbert, D., Krapcho, M. 2008. SEER cancer statistics review. *Bethesda, MD*: 1975–2005.
- Schulz, K.F., Altman, D.G., Moher, D. 2010. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. *BMJ*; 340: c332.
- Sorbye, H., Cvancarova, M., Qvortrup, C., Pfeiffer, P., Glimelius, B. 2013. Age-dependent improvement in median and long-term survival in unselected

- population-based Nordic registries of patients with synchronous metastatic colorectal cancer. *Ann Oncol*. Sep;24(9):2354-60.
- Sung, J.J., Lau J.Y., Goh K.L., Leung W.K. 2005. Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. *Lancet Oncol*; 6: 871-876.
- Suzanna, E.S. 2012. Registrasi Kanker Berbasis Rumah Sakit di Rumah sakit Kanker Dharmais 2003-2007. Laporan Kerja Subbagian Registrasi Kanker. *Departemen Kesehatan Republik Indonesia*.
- Tebbutt, N.C., Wilson, K., GebSKI, V.J. 2010. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. *J Clin Oncol*; 28: 3191–3198.
- Teixeira,M.C., Marques, D.F., Ferrari,A.C., Alves,M.F., Alex,A.K., Sabbaga, J., Hoff,P.M., Riechelmann, R.P. 2010. The Effects of Palliative Chemotherapy in Metastatic Colorectal Cancer Patients With an ECOG Performance Status of 3 and 4. *Clin Col Cancer*: 14(1) 52-7.
- Tournigand, C., André, T., Achille, E. 2004. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. *J Clin Oncol*; 22: 229–237.
- Van Cutsem, E., Cervantes, A., Nordlingers, B. 2014. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow up. *Annals of Oncology*; 25 (Supplement 3): iii1–iii9.
- World Cancer Research Fund and American Institute for Cancer Research, 2007. Food, Nutrition, Physical Activity, and the Prevention of Cancer: A Global Perspective. *American Institute for Cancer Research*; Washington, DC.